Piper Sandler Assumes Mirati Therapeutics at Overweight, Announces Price Target of $45
Portfolio Pulse from richadhand@benzinga.com
Piper Sandler analyst Swapnil Malekar has assumed Mirati Therapeutics (NASDAQ:MRTX) with an Overweight rating and announced a price target of $45.
August 09, 2023 | 12:43 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Mirati Therapeutics has been assumed with an Overweight rating by Piper Sandler analyst Swapnil Malekar, who has set a price target of $45.
The Overweight rating by Piper Sandler indicates a positive outlook for Mirati Therapeutics. The price target of $45 suggests that the analyst believes the stock has significant upside potential. This could lead to increased investor interest and a potential rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100